Esperion Therapeutics (ESPR) Revenue (2019 - 2026)

Esperion Therapeutics' Revenue history runs 8 years deep, the most recent figure standing at $80.1 million for Q1 2026.

• Quarterly Revenue rose 23.25% year-over-year to $80.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418.2 million (up 61.13% YoY) and the FY2025 annual result came in at $403.1 million, up 21.31% from the prior year.
• Revenue was $80.1 million for Q1 2026 at Esperion Therapeutics, down from $168.4 million in the prior quarter.
• Across five years, Revenue topped out at $168.4 million in Q4 2025 and bottomed at $18.8 million in Q4 2022.
• A 5-year average of $59.3 million and a median of $51.6 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue plunged 53.66% — and 2024, when it surged 466.14%.
• Esperion Therapeutics' Revenue stood at $18.8 million in 2022, then soared by 71.38% to $32.2 million in 2023, then surged by 114.3% to $69.1 million in 2024, then surged by 143.73% to $168.4 million in 2025, then sank by 52.45% to $80.1 million in 2026.
• Business Quant data shows ESPR's Revenue at $80.1 million in Q1 2026, $168.4 million in Q4 2025, and $87.3 million in Q3 2025.